Therapeutic anticoagulation effectively prevents recurrent thrombosis for a majority of patients with venous thromboembolism (VTE), with recurrence rates of approximately 2% using the direct oral anticoagulants (DOACs).
Res Pract Thromb Haemost. 2019;3:498-502. wileyonlinelibrary.com/journal/rth2 Therapeutic anticoagulation effectively prevents recurrent thrombosis for a majority of patients with venous thromboembolism (VTE), with recurrence rates of approximately 2% using the direct oral anticoagulants (DOACs) . 1 Yet the possibility of VTE recurrence, often colloquially referred to as "breakthrough thrombosis" or "anticoagulant failure," creates anxiety for patients and providers and remains a clinical dilemma for multiple reasons, including a lack of consistent radiographic criteria for diagnosing recurrent VTE, poor correlation between persistent or recurrent VTE symptoms and true breakthrough thrombosis, and the lack of validated "therapeutic" plasma DOAC drug levels to prove appropriate DOAC dosing. 2, 3 But might our commonly held definitions of breakthrough misrepresent a natural physiologic process? Interestingly, abundant data from early studies of heparin and vitamin K antagonists (VKAs) that employed serial imaging reveal a relatively high rate of asymptomatic thrombus propagation early in the course of VTE treatment. Herein, we synthesize this literature and submit that incidentally detected, asymptomatic thrombus propagation within 30 days of initial VTE
should not be interpreted as breakthrough or anticoagulation failure.
Rather, these patients can be safely monitored for new or worsening symptoms with continuation of their current therapy.
Unlike modern trials, many early studies of heparins and VKAs for acute VTE management performed serial imaging after the initial VTE diagnosis to screen for asymptomatic thrombus propagation. After initiating therapeutic anticoagulation, repeat imaging studies (typically contrast venography or compression ultrasonography with Doppler)
were repeated at various intervals. Descriptions of select studies of deep vein thrombosis (DVT) treatment and asymptomatic thrombus propagation rates are shown in Table 1 . Collectively, these studies reveal that despite therapeutic anticoagulation, DVT propagation can be detected in a substantial proportion of patients. In multiple single-arm cohort studies, propagation occurred in 10% to 38% of patients within the first 14 days of treatment despite therapeutic anticoagulation. [4] [5] [6] [7] [8] [9] Several RCTs comparing unfractionated heparin (UFH) to low-molecular-weight heparin (LMWH) also occasionally included serial screening imaging studies and found propagation rates ranging from 1.1%
to 15%, again within the first 10 to 14 days of therapy. [10] [11] [12] and found symptomatic thrombus propagation rates from 0.3% to 4.2% within the first 6 weeks of anticoagulation. 13, 14 Perhaps reflecting these propagation rates, a state-of-the-art ultrasound guideline in 1993 stressed the "dubious" role of serial imaging in patients with anticoagulant-treated DVT. 15 Similarly, the Society for Vascular Medicine's "Choosing Wisely" guidelines recommend against serial imaging of established DVT in the absence of worsening symptoms.
These results must be interpreted in the context of significant heterogeneity in study execution, including variable subject inclusion criteria; lack of information on concurrent use of antiplatelet medications; and inconsistent anticoagulant dosing, imaging modalities utilized, and criteria to define worsening thrombosis. Confounding factors affecting detectable VTE progression should also be considered: In several studies, patients were below the therapeutic range of either heparin or VKAs for up to a third of the study time. 
TA B L E 1 (Continued)
Along these lines, the activated partial thromboplastin time (APTT), though often used in these studies, has largely been replaced by the anti-Xa assay for measuring blood levels of heparin products given its superior sensitivity and specificity. is recognized that scarring of the vessel wall and turbulent blood flow after DVT can be difficult to differentiate from fresh thrombus, potentially leading to false positives. 3 The natural history of untreated DVT would serve as a useful comparison, though such data are limited; for untreated, isolated, distal lower extremity VTE followed with serial imaging, a systematic review described a proximal propagation rate of 10%. 17 Acknowledging the risks of cross-trial comparisons, this rate falls within the range of propagation rates discussed above for treated patients. Third, it is unclear whether the rates of early, asymptomatic DVT propagation can be extrapolated to cases of pulmonary embolism (PE). Importantly, the majority of studies listed in Table 1 described patients with DVT only. While the pathophysiologic concepts of inflammation and thrombus remodeling discussed above could reasonably apply to multiple forms of venous thrombosis, data for asymptomatic PE propagation is less abundant and beyond the scope of this discussion. Similarly, it also remains unclear whether asymptomatic thrombus propagation seen with heparins and VKA should also be expected with DOACs. Modern trials leading to DOAC approvals have reported only aggregate, symptomatic VTE recurrence without patient-level outcomes, and thus early propagation rates with DOACs remain largely unknown. The noninferiority, and in some cases superiority, of DOACs compared to heparins and VKAs for VTE treatment reported in major trials, however, makes it unlikely that thrombus propagation rates would be higher with DOACs. 1 Finally, the precise time at which thrombus propagation is no longer expected remains to be clarified. Guidelines from the ISTH suggest criteria for diagnosing recurrent DVT, including elevated D-dimer measurements and a difference in residual vein diameter >4 mm between serial ultrasound images, though these guidelines do not define when such findings justify treatment changes. 18 We reason that based on available data, a cutoff of ~30 days would seem reasonable, and that asymptomatic thrombus propagation diagnosed within this time frame can be ignored with no changes in anticoagulant therapy. However, a practice of close clinical follow-up and heightened patient vigilance for symptoms of worsening DVT should be followed. We do not recommend serial imaging to monitor for further progression in the absence of symptoms; while this practice is advised for some cases of untreated superficial and distal lower extremity venous thrombosis, with initiation of anticoagulation if thrombus propagates closer to the proximal deep veins, evidence is lacking for the same strategy in cases of treated proximal DVT with asymptomatic progression. 19 As data on outcomes of symptomatic DVT progression without changes in anticoagulant therapy are scarce, we feel that these cases cannot be dismissed and that switching to an alternative anticoagulant should be strongly considered, as recommended in a recent review by Schulman et al. 20 Several potential strategies for future research could help address knowledge gaps in the management of thrombosis progression or breakthrough. First, it would be helpful to know the rates of asymptomatic VTE propagation in patients treated with DOACs, which should consist of frequent screening imaging in a prospective randomized or cohort VTE treatment trial. This study outcome should also be applied to patients treated specifically for PE, to clarify whether this form of venous thrombosis should be considered distinct. In conjunction, prospectively tracking clinically relevant longterm outcomes of asymptomatic thrombus propagation, including development of PTS, recurrent VTE, and mortality would also help to clarify the true clinical significance of this entity. Also aiding in the distinction between symptomatic and asymptomatic thrombus propagation could be a change in the naming conventions of these entities, such that "breakthrough" refers only to symptomatic or late (>30 days) propagation. Ultimately, these strategies could help to further narrow our definitions of "breakthrough" or anticoagulation "failure," helping medical providers avoid unnecessary changes in therapy and reducing both provider and patient anxiety.
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